Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | CTSB | P07858 | 4/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22170 | 0.91 | DAO (0.50) | ALDH1A1DAORAB9ANPC1MAOB | |
| SCHEMBL10504274 | 0.76 | CYP1A2 (0.45) | ALDH1A1DAORAB9ANPC1L3MBTL1 | |
| Acetonitrile SCHEMBL28796785 | 0.75 | MAPK1 (0.36) | ALDH1A1MAPK1TDP1 | |
| SCHEMBL7058887 | 0.74 | NPC1 (0.51) | ALDH1A1RAB9ANPC1MAOBMAOA | |
| SCHEMBL10503242 | 0.74 | DAO (0.50) | ALDH1A1DAORAB9ANPC1L3MBTL1 | |
| SCHEMBL31025428 | 0.70 | MAOA (0.34) | ALDH1A1DAOACMSDRAB9AMAOB | |
| SCHEMBL11219053 | 0.68 | — | — | |
| SCHEMBL6408107 | 0.66 | ALDH1A1 (0.67) | ALDH1A1DAORAB9ANPC1MAOB | |
| SCHEMBL10369265 | 0.66 | RAB9A (0.49) | ALDH1A1RAB9ANPC1 | |
| SCHEMBL9199735 | 0.66 | LMNA (0.46) | ALDH1A1RAB9ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741503-A1 | RNAI AGENT FOR INHIBITING AGT GENE EXPRESSION AND USE THEREOF | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| US-20250346902-A1 | RNAI AGENT INHIBITING PCSK9 GENE EXPRESSION AND APPLICATION THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2025-11-13 | — | — | US | disclosed |
| CN-120019147-A | Antisense oligonucleotide for inhibiting trpv1 gene expression and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2025-05-16 | — | — | CN | disclosed |
| CN-119816597-A | DsRNA molecule for inhibiting HBV gene expression and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2025-04-11 | — | — | CN | disclosed |
| CN-119816596-A | DsRNA molecule for inhibiting C5 gene expression and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2025-04-11 | — | — | CN | disclosed |
| CN-119585433-A | RNAi agent for inhibiting AGT gene expression and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-119563025-A | DsRNA molecule for inhibiting expression of LP (a) gene and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2025-03-04 | — | — | CN | disclosed |
| EP-4464781-A1 | RNAI AGENT INHIBITING PCSK9 GENE EXPRESSION AND APPLICATION THEREOF | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2024-11-20 | — | — | EP | disclosed |
| CN-118786216-A | RNAi agent for inhibiting PCSK9 gene expression and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2024-10-15 | — | — | CN | disclosed |
| CN-118679174-A | Modified nucleoside monomer and double-stranded ribonucleic acid | 石药集团中奇制药技术（石家庄）有限公司 | 2024-09-20 | — | — | CN | disclosed |
| CN-117580846-A | Compounds with liver targeted delivery effect and oligonucleotide conjugates thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2024-02-20 | — | — | CN | disclosed |
| WO-2023208106-A1 | COMPOUND HAVING LIVER-TARGETING DELIVERY EFFECT AND OLIGONUCLEOTIDE CONJUGATE THEREOF | 石药集团中奇制药技术（石家庄）有限公司 | 2023-11-02 | — | — | WO | disclosed |
| US-20200172903-A1 | ENA ANTISENSE OLIGONUCLEOTIDE FOR INHIBITION OF alpha-SYNUCLEIN EXPRESSION | OSAKA UNIVERSITY (JP) | 2020-06-04 | — | — | US | disclosed |
| EP-3628737-A1 | ENA ANTISENSE OLIGONUCLEOTIDE FOR INHIBITION OF ALPHA-SYNUCLEIN EXPRESSION | Osaka University (JP) | 2020-04-01 | — | — | EP | disclosed |
| EP-2458005-A1 | FGF21 CIS-ELEMENT BINDING SUBSTANCE | Galaxy Pharma Inc. (JP) | 2012-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172903-A1 | ENA ANTISENSE OLIGONUCLEOTIDE FOR INHIBITION OF alpha-SYNUCLEIN EXPRESSION | SNCA, ENO1, ENY2 | ALDH1A1 849/4885DAO 667/4885ACMSD 4734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.